Metformin and long non-coding RNAs in breast cancer.
Morteza GholamiZeynab Nickhah KlashamiPirooz EbrahimiAmir Ali MahboobipourAmir Salehi FaridAida VahidiMarziyeh ZoughiMojgan AsadiMahsa M. AmoliPublished in: Journal of translational medicine (2023)
Breast cancer (BC) is the second most common cancer and cause of death in women. In recent years many studies investigated the association of long non-coding RNAs (lncRNAs), as novel genetic factors, on BC risk, survival, clinical and pathological features. Recent studies also investigated the roles of metformin treatment as the firstline treatment for type 2 diabetes (T2D) played in lncRNAs expression/regulation or BC incidence, outcome, mortality and survival, separately. This comprehensive study aimed to review lncRNAs associated with BC features and identify metformin-regulated lncRNAs and their mechanisms of action on BC or other types of cancers. Finally, metformin affects BC by regulating five BC-associated lncRNAs including GAS5, HOTAIR, MALAT1, and H19, by several molecular mechanisms have been described in this review. In addition, metformin action on other types of cancers by regulating ten lncRNAs including AC006160.1, Loc100506691, lncRNA-AF085935, SNHG7, HULC, UCA1, H19, MALAT1, AFAP1-AS1, AC026904.1 is described.
Keyphrases
- long non coding rna
- poor prognosis
- network analysis
- type diabetes
- genome wide analysis
- genome wide identification
- risk factors
- papillary thyroid
- squamous cell carcinoma
- metabolic syndrome
- adipose tissue
- dna methylation
- genome wide
- transcription factor
- room temperature
- childhood cancer
- binding protein
- weight loss
- pregnancy outcomes
- skeletal muscle
- replacement therapy